UAB 1640-Phase II Trial of Vosaroxin in Combination with Infusional Cytarabine in Patients with Untreated AML

Grant

Date/time Interval

  • January 18, 2017 - January 17, 2022
  • Awarded By

    Total Award Amount

  • 66074.00
  • Direct Costs

  • 50826.00
  • Sponsor Award Id

  • Contributor

  • Erba, Harry   Principal Investigator  
  • Papadantonakis M.D., Ph.D., Nikolaos   Investigator